USPTO Art Unit 1691 Prosecution Statistics

Art Unit Information

Art Unit: 1691
Group: 1690
Tech Center: 1600
Total Cases: 1,258
Last Active: March 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19079070FORMULATIONS OF VIMSELTINIBMarch 2025May 2025Allow200YesNo
19025101CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDEJanuary 2025June 2025Allow510NoNo
19018702ILOPROST COMPOSITIONS AND FORMULATIONS THEREOFJanuary 2025July 2025Allow610YesNo
19002520COMPOUNDS FOR ACTIVATING A SEROTONIN RECEPTORDecember 2024May 2025Allow510NoNo
18990585USE OF MARIBAVIR IN TREATMENT REGIMENSDecember 2024May 2025Allow510YesNo
18987521PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONEDecember 2024June 2025Allow610NoNo
18964637GLYCOSYLATION METHOD INVOLVING TRIVALENT IODINE REAGENTDecember 2024February 2025Allow200NoNo
18959040NOVEL PHENYLPYRAZOLE INSECTICIDE COMPOUNDS AND COMPOSITIONSNovember 2024May 2025Allow610NoNo
18951543PLEUROMUTILIN DERIVATIVE CONTAINING A THIAZOLO[5,4-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOFNovember 2024March 2025Allow401NoNo
18935099DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOFNovember 2024January 2025Allow200NoNo
18935253MODULATORS OF DCN-1 AND METHODS OF USE THEREOFNovember 2024January 2025Allow200NoNo
18932667PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEOctober 2024April 2025Allow510NoNo
18929263SELECTIVE LIGANDS FOR TAU AGGREGATESOctober 2024January 2025Allow200YesNo
18860494PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVESOctober 2024February 2025Allow400NoNo
18924252Oral (17-�)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyOctober 2024January 2025Allow310NoNo
18918161PTPN2/PTP1B Degrader and Therapeutic Method ThereofOctober 2024December 2024Allow200NoNo
18914975AZAINDOLE ROCK INHIBITORSOctober 2024January 2025Allow400YesNo
18910861HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATEROctober 2024March 2025Allow510YesNo
18910839HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATEROctober 2024February 2025Allow510YesNo
18853657ACETYL SALICYLIC ACID COMPOSITION FOR INTRAVENOUS ADMINISTRATION, ITS STORAGE, PRODUCTION AND USEOctober 2024June 2025Allow810NoNo
18898132GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATESeptember 2024March 2025Allow510NoNo
18892950REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEEDSeptember 2024March 2025Allow610YesNo
18808641COMPOUNDS FOR FGFR INHIBITIONAugust 2024February 2025Allow601NoNo
18807247SYSTEM AND METHOD FOR TRIGLYCERIDE MANUFACTUREAugust 2024June 2025Allow1011YesNo
18806346SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSESAugust 2024March 2025Allow710YesNo
18790828Dosage RegimenJuly 2024April 2025Allow910NoNo
18785350PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSJuly 2024April 2025Allow920NoNo
18783394KRAS G12C INHIBITORSJuly 2024October 2024Allow200NoNo
18832248GINGERENONE A PRODRUGS AS SENSOTHERAPEUTICS AND METHODS OF USEJuly 2024April 2025Allow801YesNo
18763243COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOFJuly 2024December 2024Allow510NoNo
18763277PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSJuly 2024September 2024Allow210NoNo
18763258COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOFJuly 2024December 2024Allow510NoNo
18751014PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024February 2025Allow810NoNo
18680287ESKETAMINE FOR THE TREATMENT OF DEPRESSIONMay 2024March 2025Abandon910NoNo
18670619EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024April 2025Abandon1120NoNo
18664971CD206 TARGETED DRUG DELIVERY VEHICLES CARRYING NOVEL BISPHOSPHONATE DRUG PAYLOADS VIA A DEGRADABLE LINKERMay 2024January 2025Allow810NoNo
18660547PREPARATION METHOD FOR POLYSACCHARIDE SPHERICAL GEL RESINMay 2024April 2025Allow1120NoNo
18656519TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTIONMay 2024March 2025Abandon1010NoNo
18616046COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USEMarch 2024November 2024Allow811YesNo
18610897IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLESMarch 2024June 2025Allow1521YesNo
18442232SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICSFebruary 2024June 2025Abandon1610NoNo
18438965ALL-AROMATIC LIQUID-CRYSTALLINE HOMO-POLYIMIDES WITH AROMATIC ENDGROUPS AND CROSSLINKED PRODUCTS THEREFROMFebruary 2024April 2025Allow1400YesNo
18435857DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORSFebruary 2024February 2025Allow1300NoNo
18435109PRODRUGS OF L-BHDU AND METHODS OF TREATING VIRAL INFECTIONSFebruary 2024June 2025Allow1710NoNo
18429785System and method for non-surgical treatment of prolapsed hemorrhoidsFebruary 2024March 2025Allow1313YesNo
18428938PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATEJanuary 2024June 2025Allow1611NoNo
18425648ALTERING CANCER CELLULAR FUNCTIONS THROUGH PROTON MOPPINGJanuary 2024June 2025Abandon1710NoNo
18419354NOVEL EBSELEN ANALOGUES LOADED NANOEMULSIONJanuary 2024August 2024Allow710NoNo
18409952COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONSJanuary 2024February 2025Allow1400YesNo
18406732METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTORJanuary 2024March 2025Allow1410NoNo
18577214NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMSJanuary 2024February 2025Allow1410NoNo
18405593COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTSJanuary 2024June 2025Allow1810NoNo
18394155COMPOSITION COMPRISING COMBINATION OF RAPAMYCIN AND METFORMIN AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASESDecember 2023May 2025Allow1710NoNo
18530920METHODS AND COMPOSITIONS FOR THERAPEUTIC SKIN TREATMENTS IN DERMATOLOGICAL PROCEDURES AFFECTING SKIN'S BARRIERDecember 2023June 2025Allow1910YesNo
18530017ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITHDecember 2023June 2025Allow1810NoNo
18567332BIOMASS PRODUCTIONDecember 2023September 2024Allow910YesNo
18566281METHOD FOR OBTAINING BIO-SOURCED N-VINYLFORMAMIDEDecember 2023December 2024Allow1210YesNo
18523772METHOD TO ALLEVIATE THE SYMPTOMS OF PMSNovember 2023February 2025Allow1400NoNo
18519408ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOGNovember 2023February 2025Allow1510NoNo
18518436NOVEL METHODSNovember 2023May 2025Allow1830NoYes
18515464COMPOSITIONS AND METHODS FOR SOLIDIFIED FERMENTED ANIMAL FEEDNovember 2023February 2025Allow1500NoNo
18516459MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOFNovember 2023July 2025Allow1920NoNo
18516626PROCESS FOR MAKING A PD-1/PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOFNovember 2023April 2025Allow1601NoNo
18513436DISSOLVABLE NASAL SINUS SPONGENovember 2023May 2025Allow1810YesNo
18389006SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTIONNovember 2023April 2025Allow1710NoNo
18388753METHODS, KITS, AND COMPOSITIONS FOR PROCESSING EXTRACELLULAR MOLECULESNovember 2023April 2025Allow1820YesNo
18506169METHODS FOR TREATING AND PHARMACEUTICAL COMPOSITIONSNovember 2023June 2025Allow1910YesNo
18502589COMPOSITIONS AND USES THEREOF FOR TREATMENT OF IDIOPATHIC PRETERM BIRTHNovember 2023June 2025Allow2000NoNo
18502240TREATING IRON DEFICIENCY WITH FERRIC CARBOXYMALTOSENovember 2023September 2024Allow1020YesNo
18500175TOPICAL FERTILITY PROMOTING PRODUCT AND MANUFACTURING METHODNovember 2023May 2025Allow1810NoNo
18498102NON-PEPTIDIC CELL-PENETRATING MOTIFSOctober 2023March 2025Allow1611YesNo
18382307TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORSOctober 2023January 2025Allow1521YesNo
18287610PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASEOctober 2023July 2025Allow2010NoNo
18487690MODULATORS OF ALPHA-1 ANTITRYPSINOctober 2023January 2025Allow1610NoNo
18378011CELL-BASED ASSAY FOR QUANTIFYING THE POTENCY AND EFFICACY OF CANNABINOIDS AND/OR TERPENOIDS, AND METHODS OF USE THEREOFOctober 2023April 2025Allow1811YesNo
18480925PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3October 2023April 2025Allow1810YesNo
18480164PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3October 2023October 2024Allow1300NoNo
18476506COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSISSeptember 2023May 2025Abandon2030NoNo
18476222LONG CHAIN ALKYL ESTERAMINE LIPID COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN NUCLEIC ACID DELIVERYSeptember 2023March 2025Allow1721YesNo
18474535STABLE ORAL SUSPENSIONS OF BACLOFENSeptember 2023March 2025Allow1700YesNo
18472660Apixaban DosingSeptember 2023January 2025Allow1613YesNo
18371865FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGSSeptember 2023March 2025Allow1810NoNo
18371647INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP)September 2023March 2025Allow1820NoNo
18468266PHARMACEUTICAL COMPOSITIONS OF NILOTINIBSeptember 2023May 2025Allow2010NoNo
18465722THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATIONSeptember 2023April 2025Allow1911YesNo
18243169REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENTSeptember 2023January 2025Allow1610YesNo
18462229USE OF EZH2 INHIBITORS FOR TREATING CANCERSeptember 2023April 2025Abandon2010NoNo
18456839COMPOSITIONS FOR THE TREATMENT OF DRY EYEAugust 2023April 2025Abandon1910NoNo
18456301BRD9 DEGRADERS AND USES THEREOFAugust 2023April 2025Abandon1901NoNo
18451520METHODS OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASEAugust 2023June 2025Abandon2210NoNo
18233769Carbondisulfide Derived ZwitterionsAugust 2023September 2024Allow1311YesNo
18232033POLYMORPHS OF THE HYDROCHLORIDE SALT OF LINAPRAZAN GLURATEAugust 2023March 2025Allow2020NoNo
18232135Use of Polysaccharide for Treating ST-Elevation Myocardial Infarction and Diseases of the Digestion SystemAugust 2023December 2024Allow1610YesNo
18231035METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CALCIPHYLAXISAugust 2023June 2025Allow2210NoNo
18365549TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIBAugust 2023June 2025Abandon2210NoNo
18364058NON-LINEAR DOSING OF MIRDAMETINIBAugust 2023February 2025Allow1810NoNo
18228969FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGEAugust 2023January 2025Allow1710NoNo
18227210ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS FOR THE TREATMENT AND/OR PREVENTION OF RESPIRATORY ILLNESSESJuly 2023April 2025Allow2110NoNo
18220779INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)July 2023March 2025Abandon2010NoNo
18346721COMPOSITIONS AND METHODS OF USING PROPYLENE SULFIDE-BASED POLYMERS FOR TREATMENT OF CHAGAS DISEASEJuly 2023January 2025Allow1900YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1691.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
2
(33.3%)
Examiner Reversed
4
(66.7%)
Reversal Percentile
97.4%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
27
(55.1%)
Not Allowed After Appeal Filing
22
(44.9%)
Filing Benefit Percentile
96.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 55.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1691 - Prosecution Statistics Summary

Executive Summary

Art Unit 1691 is part of Group 1690 in Technology Center 1600. This art unit has examined 1,258 patent applications in our dataset, with an overall allowance rate of 94.4%. Applications typically reach final disposition in approximately 27 months.

Comparative Analysis

Art Unit 1691's allowance rate of 94.4% places it in the 95% percentile among all USPTO art units. This art unit has a significantly higher allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1691 receive an average of 1.21 office actions before reaching final disposition (in the 9% percentile). The median prosecution time is 27 months (in the 59% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.